High-risk human papillomavirus testing in women with ASCUS cytology: results from The ATHENA HPV study

Authors

  • M.H. Stoler University of Virginia Health System, United States
  • T.C. Wright, Jr. Columbia University School of Medicine, United States
  • A. Sharma Roche Molecular Systems, United States

DOI:

https://doi.org/10.18370/2309-4117.2021.57.93-98

Keywords:

atypical squamous cells of undetermined significance, ASCUS, cervical cancer screening, cervical intraepithelial neoplasia, CIN, cytology, genotype, human papillomavirus, HPV, HPV DNA testing, triage

Abstract

This study evaluated the clinical performance of the cobas 4800 HPV Test (Roche Molecular Systems, Pleasanton, CA, USA) for high-risk human papillomavirus (HR-HPV) testing with individual HPV-16/HPV-18 genotyping in women 21 years or older with atypical squamous cells of undetermined significance (ASCUS). Women (N = 47,208) were recruited in the United States during routine screening, and liquid-based cytology and HPV testing were performed. The ASCUS prevalence was 4.1% (1,923/47,208), and 1,578 women underwent colposcopy with valid results. The cobas 4800 HPV Test demonstrated performance comparable to the Hybrid Capture 2 test (QIAGEN, Gaithersburg, MD, USA) for the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse and grade 3 or worse. HPV-16/HPV-18+ women had a greater absolute risk of CIN 2 or worse compared with pooled HR-HPV+ and HR-HPV- women (24.4%, 14.0%, and 0.8%, respectively).
The cobas 4800 HPV Test is clinically validated for ASCUS triage. HPV-16/HPV-18 genotyping can identify women at highest risk for high-grade cervical disease, and this additional risk stratification may be used in formulating patient management decisions.

Author Biographies

M.H. Stoler, University of Virginia Health System

MD

T.C. Wright, Jr., Columbia University School of Medicine

MD, Department of Pathology

A. Sharma, Roche Molecular Systems

PhD

Published

2021-03-31

Issue

Section

International experience